Glaukos is scaling rapidly on iDose TR and Epioxa, with Q3 revenue up 58% and 2027 sales guidance topping $1.0B. The stock still screens as a Hold because premium valuation and ongoing losses leave limited margin for error.
Glaukos Corp (GKOS) has shifted from a promising ophthalmic device company into a faster-growing platform business built around iDose TR and Epioxa. Q3 2026 revenue reached $211.0M, up 58% year over year, while management raised full-year 2026 revenue guidance to $775M-$785M and introduced preliminary 2027 sales guidance of $1.0B. The operating trend is powerful, but the stock price already discounts a large share of that success.
The central investment case rests on commercial adoption rather than current earnings. iDose TR generated approximately $76M in Q3 sales, and Epioxa generated approximately $53M. Q3 non-GAAP operating income was $27.3M, compared with a $9.3M operating loss in the prior-year quarter. Those figures show a credible margin inflection, although GAAP losses, negative trailing EPS of $3.26, negative free cash flow of $38.7M in the latest reported fiscal-year data, and an EV-to-revenue multiple of 16.9x leave little room for execution errors.
At a quoted share price of $165.37, the risk-reward profile fits a Hold for a moderate-risk investor with a medium-term horizon. The $195.00 fair-value estimate reflects strong revenue visibility, high gross margins, a debt-free balance sheet, and two recently launched growth products, offset by the company's current losses, reimbursement exposure, international competition, and premium valuation.
Glaukos is an ophthalmic pharmaceutical and medical technology company founded in 1998 and headquartered in Aliso Viejo, California. The company employs 1,094 people and sells through a direct sales organization, direct subsidiaries, and distributors to ambulatory surgery centers, hospitals, and private physician practices.
The portfolio covers glaucoma, corneal disorders, and retinal disease. Commercial products include the iStent family of micro-bypass stents, iStent infinite, iDose TR, and the Epioxa and Photrexa corneal cross-linking franchise. Development platforms include iLink, iLution, and retinal programs. This mix gives Glaukos multiple opportunities to expand within ophthalmology, but it also requires sustained spending on clinical trials, regulatory submissions, sales infrastructure, and physician education.
The company's commercial identity is built around dropless or reduced-drop therapies. Its first MIGS device launched commercially in 2012, giving Glaukos a long history of surgeon training, clinical evidence, and category development. The business has treated more than 3.5 million eyes globally and operates in more than 20 countries, according to company materials.
Glaukos reported three operating franchises in Q3 2026. U.S. Glaucoma produced approximately $118.6M, up 47% year over year. International Glaucoma generated approximately $33.4M, up 13% on a reported basis and 15% in constant currency. Corneal Health delivered approximately $59.0M, up 154%, with Epioxa contributing approximately $53M.
U.S. Glaucoma remains the largest revenue engine. In Q2 2026, the franchise generated $118.5M, up 64%, and iDose TR contributed approximately $74M. Management expects U.S. Glaucoma growth of roughly 50% for 2026, with iDose TR sales of approximately $275M-$280M. The broader legacy portfolio is expected to grow at a low-single-digit rate, making iDose the primary source of incremental expansion.
International Glaucoma is smaller but strategically important because it extends the iStent and interventional glaucoma model into new markets. Management expects low-to-mid-teens growth for the full year. Competitive product trials, reimbursement pressure in Germany and Switzerland, and the fading of foreign-exchange tailwinds create a more measured outlook than the U.S. business.
Corneal Health has become the second major growth pillar. Epioxa's launch created a sharp increase in Q3 revenue, while the franchise had already produced $30.4M in Q2, up 48%. Management described a transition from Photrexa to Epioxa during the third quarter and projected roughly 20% year-over-year growth for Corneal Health in 2026.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
iDose TR is Glaukos' flagship commercial product. It is an intracameral sustained-release therapy designed to reduce intraocular pressure without the daily eye-drop burden associated with traditional treatment. The January 2026 FDA labeling supplement permits unlimited re-administration for patients who maintain a healthy cornea, expanding the product's long-term commercial use.
The product's commercial evidence is becoming more substantial. The company reported 27 peer-reviewed publications supporting iDose TR by Q3 2026. A Phase 4 study combining iDose TR with cataract surgery produced an 11.1 mmHg mean diurnal intraocular-pressure reduction at three months, compared with 7.4 mmHg for cataract surgery alone, for an incremental treatment effect of 3.6 mmHg.
Epioxa is the first and only FDA-approved epithelium-on corneal cross-linking therapy for keratoconus, according to company materials. Q3 sales of approximately $53M show that the product moved quickly from approval to meaningful commercial contribution. Its launch is supported by an O2N system network serving roughly 90% of the U.S. population, access pathways covering about 90% of commercial lives and more than 80% of Medicaid lives, and the product-specific J-code J2789, effective July 1, 2026.
The product carries launch-transition risk. Management described third-quarter volatility as Photrexa moved toward sunset and Epioxa shifted into the permanent J-code environment. The three-year extension study reported a 1.9-diopter improvement in maximum corneal curvature, with 29% of eyes gaining at least two lines of best-corrected visual acuity. Those results strengthen the clinical narrative, while the commercial model still depends on referral development, payer access, and site utilization.
Glaukos' strongest advantage is the combination of clinical infrastructure and platform breadth. The company pioneered MIGS, built an installed base of trained surgeons, and accumulated regulatory experience across devices and pharmaceuticals. That history helps reduce the friction involved in introducing new products into operating rooms and specialty practices.
The innovation pipeline spans five novel therapeutic platforms and 13 publicly disclosed programs. iDose TREX is in a Phase IIb/III program, iDose TRIO is in a Phase IIIb program, and a customized topographically guided iLink therapy is scheduled for a Phase III program in 2027. The company also has programs in Demodex blepharitis, retinal disease, and the PRESERFLO MicroShunt.
The pipeline creates valuable optionality, but it also explains the current earnings profile. Glaukos has continued to increase clinical and commercial investment while revenue accelerates. Management said second-quarter research and development spending increased by $8M sequentially, and the company continues to prioritize reinvestment behind iDose TR, Epioxa, and the broader pipeline.
Glaukos uses a specialized commercial model that combines direct sales, physician training, patient support, specialty pharmacy coordination, and distributor relationships. This model fits procedure-based ophthalmology, where clinical education and reimbursement support influence adoption as much as product awareness.
Epioxa's launch infrastructure is already broad. The company's Q3 materials described treatment systems serving roughly 90% of the U.S. population, with a pipeline intended to extend coverage beyond 95%. The company also operates patient services, co-pay assistance, and a specialty pharmacy network. These investments raise operating costs, but they also create a commercialization framework for future ophthalmic therapies.
Supply-chain execution remains a material risk. Glaukos' 2025 10-K identifies manufacturing or supply disruptions as factors that could affect gross margin and operating results. The filing also highlights the judgment involved in customer discounts, rebates, returns, and warranty replacements. That revenue complexity makes disciplined contract management important as Epioxa scales across commercial, Medicaid, and government channels.
The global MIGS devices market is estimated at $637.1M in 2026 and $781.2M in 2030. Glaukos' growth is not limited to the existing MIGS device market because iDose TR adds a sustained-release pharmaceutical model and Epioxa opens a separate corneal cross-linking category.
The U.S. opportunity is sizeable. Company materials cite approximately 12 million U.S. patients with ocular hypertension or primary open-angle glaucoma, including more than 6 million diagnosed and treated patients. Management also cited 500,000-600,000 selective laser trabeculoplasty procedures annually, providing a large procedural pool for interventional glaucoma therapies.
The broader medical device market benefits from aging populations, chronic disease prevalence, and movement toward outpatient procedures. ASCs are projected to grow faster than hospitals in the cited U.S. medical-device market research, a favorable channel trend for Glaukos because iStent and iDose procedures rely on hospital outpatient and ASC reimbursement.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Glaukos serves ophthalmic surgeons, hospitals, ambulatory surgery centers, physician practices, and distributors. The economic buyer is often a facility or payer, while the clinical decision rests with the surgeon. That structure makes product evidence, procedure economics, reimbursement, and physician familiarity central to adoption.
iDose TR adoption depends on trained surgeons and active accounts. In Q2, management described increasing utilization, broader market access, and stronger activity among commercial and Medicare Advantage patients. Five of seven Medicare administrative contractors issued proposed local coverage determinations for iDose TR during the quarter, and CMS proposed maintaining the relevant 2026 facility and physician payment structure for 2027.
Epioxa requires a different customer-development process. The company is building referral networks, optometrist engagement, disease awareness, treatment centers, payer pathways, and patient support. The Q3 access figures of about 90% of commercial lives and more than 80% of Medicaid lives show substantial early coverage work, while utilization at individual sites remains a key determinant of the product's next phase.
Alcon is the clearest direct competitor in stent-based MIGS through Hydrus Microstent. Alcon also competes in glaucoma surgery through Ex-PRESS and other anterior-segment devices. Glaukos counters that competition with the iStent brand, surgeon familiarity, clinical evidence, and the newer iDose TR platform.
Sight Sciences competes through OMNI, a canaloplasty and trabeculotomy system. Other procedure-based alternatives include Kahook Dual Blade, Streamline, Via360, Nova Eye Medical's iTrack Advance, and emerging products from Iantrek. These products do not all compete device for device, but they compete for overlapping surgeon decisions and glaucoma procedure budgets.
Glaukos' competitive edge is broader than a single implant. The company combines MIGS, sustained-release drug delivery, corneal cross-linking, and retinal development. Its high gross-margin profile, which reached approximately 88% on a non-GAAP basis in Q3, gives management room to fund commercial education and clinical evidence. The trade-off is valuation: investors are paying for future platform expansion before the income statement fully reflects it.
Regulation and reimbursement matter more to Glaukos than broad economic growth. The U.S. Quality Management System Regulation became effective on February 2, 2026, aligning device quality requirements with ISO 13485:2016. EUDAMED became mandatory for use in the European Union on May 28, 2026. Both developments increase compliance demands for medical-device companies operating across regions.
Foreign exchange was a tailwind in the first half of 2026, and management expects that benefit to fade in the second half. International Glaucoma also faces reimbursement headwinds in Germany and Switzerland and competitive product trialing in major markets. These factors do not undermine the U.S. growth story, but they reduce the predictability of the international contribution.
The reimbursement environment is improving in some areas and remains contested in others. CMS proposed maintaining key payment assignments for 2027, while five of seven Medicare administrative contractors issued proposed iDose TR coverage determinations. Epioxa's product-specific J-code became effective July 1, 2026. The combination of payment rules, coverage policies, and administrative execution will influence how quickly commercial adoption converts into cash flow.
Glaukos carries a debt-free balance sheet, but its latest reported fiscal-year free cash flow was negative $38.7M, so the company is still funding growth before it can fully self-finance.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q3 non-GAAP operating income swung to $27.3M from a $9.3M loss a year ago, showing a real margin inflection even as GAAP losses remain.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management raised 2026 revenue guidance to $775M-$785M and introduced preliminary 2027 sales guidance of $1.0B, with iDose TR expected to contribute roughly $275M-$280M this year.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At an EV-to-revenue multiple of 16.9x, Glaukos trades at a premium that leaves little room for execution missteps despite its fast growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →With the stock quoted at $165.37 and our fair value at $195, the current setup points to modest upside rather than a deep discount.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Glaukos has built a rare combination of category leadership, high gross margins, regulatory expertise, and multiple ophthalmic growth platforms. Q3 2026 provided the clearest evidence yet that iDose TR and Epioxa are becoming material commercial products, while the rise in non-GAAP operating income points toward operating leverage.
The investment is still a transition story. The company needs to turn revenue growth into repeatable GAAP profitability and free cash flow while managing reimbursement, manufacturing, competition, and clinical-development demands. At $165.37, the stock offers substantial business quality but only moderate valuation protection. The balanced conclusion is Hold, with $155.00 or below providing a more attractive entry point and $195.00 serving as the report's single fair-value estimate.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Glaukos Corporation (GKOS) jumps after a strong third-quarter report featuring record sales, rapid corneal-health growth, positive net income, and higher 2026 guidance. The move reflects renewed investor confidence in the company’s ophthalmology platform, though the stock now trades near the top of analyst expectations.
The MBA 30-year mortgage rate slipped to 7.37%, its lowest in three weeks, and mortgage applications rose 3.4% after a seven-week slide. But purchase demand remains 18% below year-ago levels, underscoring how high borrowing costs continue to strain the housing market.
The Federal Reserve kept rates unchanged at 3.75%-4.00% and signaled inflation is still too high to ease policy. Markets barely blinked, but December hike odds jumped to 85%, keeping the higher-for-longer rate outlook firmly in place.